TY - JOUR
T1 - Polyelectrolyte complexes stabilize and controllably release vascular endothelial growth factor
AU - Huang, Min
AU - Vitharana, Samadhi N.
AU - Peek, Laura J.
AU - Coop, Tina
AU - Berkland, Cory
PY - 2007/5
Y1 - 2007/5
N2 - Angiogenesis has long been a desired therapeutic approach to improve clinical outcomes of conditions typified by ischemia. Vascular endothelial growth factor (VEGF) has demonstrated the ability to generate new blood vessels in vivo, but trials using intravenous delivery have not yet produced clinical success. Localized, sustained delivery of VEGF has been proven necessary to generate blood vessels as demonstrated by implantable, controlled release devices. Ultimately, nanoparticles delivered by intravenous injection may be designed to accumulate in target tissues and sustain the local VEGF concentration; however, injectable nanosuspensions that control the release of stabilized VEGF must first be developed. In this study, we utilize the heparin binding domain of VEGF to bind the polyanion dextran sulfate, resulting in an enhanced thermal stability of VEGF. Coacervation of the VEGF-bound dextran sulfate with selected polycations (chitosan, polyethylenimine, or poly-L-lysine) produced nanoparticles ∼250 run in diameter with high VEGF encapsulation efficiency (50-85%). Release of VEGF from these formulations persisted for > 10 days and maintained high VEGF activity as determined by ELISA and a mitogenic bioassay. Chitosan-dextran sulfate complexes were preferred because of their biodegradability, desirable particle size (∼250 nm), entrapment efficiency (∼85%), controlled release (near linear for 10 days), and mitogenic activity.
AB - Angiogenesis has long been a desired therapeutic approach to improve clinical outcomes of conditions typified by ischemia. Vascular endothelial growth factor (VEGF) has demonstrated the ability to generate new blood vessels in vivo, but trials using intravenous delivery have not yet produced clinical success. Localized, sustained delivery of VEGF has been proven necessary to generate blood vessels as demonstrated by implantable, controlled release devices. Ultimately, nanoparticles delivered by intravenous injection may be designed to accumulate in target tissues and sustain the local VEGF concentration; however, injectable nanosuspensions that control the release of stabilized VEGF must first be developed. In this study, we utilize the heparin binding domain of VEGF to bind the polyanion dextran sulfate, resulting in an enhanced thermal stability of VEGF. Coacervation of the VEGF-bound dextran sulfate with selected polycations (chitosan, polyethylenimine, or poly-L-lysine) produced nanoparticles ∼250 run in diameter with high VEGF encapsulation efficiency (50-85%). Release of VEGF from these formulations persisted for > 10 days and maintained high VEGF activity as determined by ELISA and a mitogenic bioassay. Chitosan-dextran sulfate complexes were preferred because of their biodegradability, desirable particle size (∼250 nm), entrapment efficiency (∼85%), controlled release (near linear for 10 days), and mitogenic activity.
UR - http://www.scopus.com/inward/record.url?scp=34249898340&partnerID=8YFLogxK
U2 - 10.1021/bm061211k
DO - 10.1021/bm061211k
M3 - Article
C2 - 17428030
AN - SCOPUS:34249898340
SN - 1525-7797
VL - 8
SP - 1607
EP - 1614
JO - Biomacromolecules
JF - Biomacromolecules
IS - 5
ER -